Rituximab and Monitoring Strategies for Late Antibody-Mediated Rejection After Kidney Transplantation

Rituximab and Monitoring Strategies for Late Antibody-Mediated Rejection After Kidney Transplantation

Background. There is limited information on treatment strategies and monitoring strategies for late antibody-mediated rejection (ABMR) after kidney transplantation. Methods. In this observational and nonrandomized study, we compared 78 patients diagnosed with late ABMR (>3 months after transplant...

Full description

Bibliographic Details
Main Authors: Sandesh Parajuli, MD, Didier A. Mandelbrot, MD, Brenda Muth, NP, Maha Mohamed, MD, Neetika Garg, MD, Fahad Aziz, MD, Robert R. Redfield, MD, Weixiong Zhong, MD, PhD, Brad C. Astor, PhD, Arjang Djamali, MD
Format: Article
Language:English
Published: Wolters Kluwer 2017-12-01
Series:Transplantation Direct
Online Access:http://journals.lww.com/transplantationdirect/fulltext/10.1097/TXD.0000000000000746

Internet

http://journals.lww.com/transplantationdirect/fulltext/10.1097/TXD.0000000000000746

Similar Items